SJS/TEN 2019: From Science to Translation

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are potentially life-threatening, immune-mediated adverse reactions characterized by widespread erythema, epidermal necrosis, and detachment of skin and mucosa. Efforts to grow and develop functional international collaborations and a multidisciplinary interactive network focusing on SJS/TEN as an uncommon but high burden disease will be necessary to improve efforts in prevention, early diagnosis and improved acute and long-term management. SJS/TEN 2019: From Science to Translation was a 1.5-day scientific program held April 26-27, 2019, in Vancouver, Canada. The meeting successfully engaged clinicians, researchers, and patients and conducted many productive discussions on research and patient care needs

Patch testing as a diagnostic modality in patients developing presumed drug-induced hypersensitivity syndromes on abacavir and Nonnucleoside Reverse Transcriptase Inhibitors (NRTIs)

Oral and Poster presentatio

Allergic reactions to bisphosphonates

No abstract availabl

Abacavir hypersensitivity syndrome: A new diagnostic test

No abstract availabl

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

A diagnostic test would be useful to help eliminate the associated morbidity and mortality after full-dose rechallenge with abacavir in patients with suspected hypersensitivity. We describe seven patients with syndromes compatible with abacavir hypersensitivity who had positive patch tests. Immunohistochemistry on skin biopsies from the acute prospectively identified patients with rash (n = 3) matched those from positive-patch patients (n = 7), suggesting an identical pathophysiological process. No patients developed systemic symptoms or signs during patch testing

Serious dermatologic reaction associated with valdecoxib: Report of two cases

To the Editor: Valdecoxib, a cyclo-oxygenase-2 inhibitor, is generally well tolerated although severe cutaneous adverse reactions have been reported to the manufacturer early in the postmarketing phase of this drug. We report two patients who developed fever, malaise, and an unusual purpuric eruption associated with valdecoxib use

A review of drug patch testing and implications for HIV clinicians

Systemic drug-induced hypersensitivity reactions (HSRs) have been reported for a variety of drugs, and are thought to have a combined immunological, genetic and metabolic basis. These diverse idiosyncratic reactions are both drug and host dependent, and subsequent rechallenge with the drugs responsible can result in a potentially life-threatening clinical reaction.Hypersensitivity has been observed in regard to several drugs used to manage HIV and associated infections, with the antiretrovirals nevirapine and abacavir being the best characterized of the syndromes. These events represent a high cost both to the patient and the healthcare system, and those labelled as being hypersensitive to one or both drugs may find their treatment options significantly reduced.The identification of HSRs can be challenging due to the heterogeneity of their clinical manifestations. Furthermore, with multidrug regimens - common in HIV management - it may be difficult to identify the drug responsible. Epicutaneous patch testing, a procedure well established in contact dermatitis, has also been used as a supplementary diagnostic test for several drug-related HSRs; its usefulness, however, depends on both the drug and syndrome involved. This study discusses HSRs and the application of patch testing to their investigation, with particular emphasis on HIV and abacavir - the antiretroviral with which patch testing has been most studie

Cross-reactivity between ampicillin and cephalexin in patients with isolated delayed skin test responses to ampicillin

Oral presentatio

A review of drug patch testing and implications for HIV clinicians

Systemic drug-induced hypersensitivity reactions (HSRs) have been reported for a variety of drugs, and are thought to have a combined immunological, genetic and metabolic basis. These diverse idiosyncratic reactions are both drug and host dependent, and subsequent rechallenge with the drugs responsible can result in a potentially life-threatening clinical reaction.Hypersensitivity has been observed in regard to several drugs used to manage HIV and associated infections, with the antiretrovirals nevirapine and abacavir being the best characterized of the syndromes. These events represent a high cost both to the patient and the healthcare system, and those labelled as being hypersensitive to one or both drugs may find their treatment options significantly reduced.The identification of HSRs can be challenging due to the heterogeneity of their clinical manifestations. Furthermore, with multidrug regimens - common in HIV management - it may be difficult to identify the drug responsible. Epicutaneous patch testing, a procedure well established in contact dermatitis, has also been used as a supplementary diagnostic test for several drug-related HSRs; its usefulness, however, depends on both the drug and syndrome involved. This study discusses HSRs and the application of patch testing to their investigation, with particular emphasis on HIV and abacavir - the antiretroviral with which patch testing has been most studie

Clindamycin-associated acute generalized exanthematous pustulosis

No abstract availabl